MRC1 and breast carcinoma: In contrary, about half of all clinicians considered the female patient to have high risks of breast or ovarian cancers (which is another concern as MMR mutation carriers have up to 14% increased risk of ovarian cancer, and breast cancer has yet to be recognized as part of the Lynch syndrome spectrum of tumours) [4].